Primary-source record

Decision-gradeAdvisory committee scheduled

Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125842 From Capricor, Inc. for Deramiocel (Human Allogeneic Cardiosphere-Derived Cells)

The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

Key facts

Filed
Jun 29, 2026, 12:00 AM
Event
Advisory committee scheduled
Direction
Neutral
Confidence
Sourced
Calendar
Advisory committee · Jun 29, 2026 · Outcome not recorded

Source excerpt

The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

Federal Register

More on this asset

Sep 22, 2026
03:22 PM
CAPRCapricor

Deramiocel · NCT04428476 registry update

Trial registry changeClinicalTrials.gov
Jun 26, 2026
01:05 PM
CAPRCapricor

Capricor to present 5-year HOPE-2 OLE and HOPE-3 Ph3 data at PPMD 2026

Conference presentationCompany press release
Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125842 From Capricor, Inc. for Deramiocel (Human Allogeneic Cardiosphere-Derived Cells) | SimianX AI